key: cord-1000314-2op9f1aj authors: Portsmore, Sophie; Tran Nguyen, Thien Ngoc; Beacham, Emma; Neelakantan, Pratap title: Combined IL‐6 and JAK‐STAT inhibition therapy in COVID‐19 related sHLH, potential game changer date: 2020-06-25 journal: Br J Haematol DOI: 10.1111/bjh.16966 sha: 7399e9f9d9772ca31855e00fd8d60d66d14850ce doc_id: 1000314 cord_uid: 2op9f1aj Coronavirus disease 2019 (COVID‐19), caused by novel SARS‐CoV‐2, leads to significant mortality and morbidity with increasing evidence for inflammatory pathways being implicated in the lung damage it causes. (1,2) Severe COVID‐19 patients present with increased inflammatory markers, akin to secondary haemophagocytic lymphohistiocytosis (sHLH), that have been shown to predict mortality. (3,4) There is emerging evidence for the use of an interleukin 6 (IL‐6) inhibitor, tocilizumab (TCZ), for suppression of the inflammatory cytokine storm in this context. (5–7) Ruxolitinib (RXB), a JAK‐STAT inhibitor, has also been shown to have proven efficacy in the treatment of sHLH. (8) Both agents appear to be promising in the fight against SARS‐CoV‐2 infection, (9,10) leading to an increasing number of trials being registered with their use. (11,12) Until this point, no single agent has shown a survival benefit against SARS‐CoV‐2 and it is possible that monotherapy may not suppress inflammation enough to overcome the COVID‐19 related cytokine storm and hyper‐inflammation. This article is protected by copyright. All rights reserved A 74-year-old female presented with fevers. She had recovered from an autograft for high-grade B-cell lymphoma two months prior. Initial investigations showed pancytopenia with elevated C-reactive protein (CRP), patchy left-sided opacification on her chest X-ray (CXR), normal oxygen saturations and a positive SARS-CoV-2 swab. She was treated for neutropenic sepsis and was discharged after eleven days. She re-presented three days later (day 0) with confusion, breathlessness and fever. CXR showed changes consistent with COVID infection as shown in figure 2. She commenced broad-spectrum antibiotics but became increasingly hypoxic requiring continuous positive airway pressure (CPAP) ventilation. On day 3 her ferritin rose to 25,600 ng/l (from 11,800 ng/l on admission) and her oxygen requirement increased. At this point, RXB was commenced to treat COVID-19-related sHLH (HScore: 214). By day 8 there was no clinical improvement despite maximal medical management; her breathing became more laboured and she was tiring. The decision was made to give TCZ along with treatment-dose low-molecular-weight heparin (LMWH) as a final attempt to treat sHLH (HScore: 185). 24 hours later, she improved clinically. On day 15 she was weaned off CPAP and completed a weaning course of prednisolone following 2 weeks of RXB. She was discharged one month after readmission. A 54-year-old male was admitted with fevers, cough and breathlessness (day 0). He had a history of non-Hodgkin's lymphoma and had been in remission for the last nine months. Initial investigations demonstrated a raised CRP, bilateral consolidation on his CXR and a positive SARS-CoV-2 swab. Broadspectrum antibiotic treatment was commenced, and he was enrolled on the RECOVERY trial (12) and randomised to lopinavir and ritonavir. On day 8 he desaturated and was started on CPAP. A CT scan showed COVID-19-related lung changes. HI initial CXR findings, subsequent worsening on CT are shown in figure 2. Due to further respiratory deterioration, he was intubated on day 16. On day 17 his ferritin level was 80,000 ng/l. He was started on TCZ to treat COVID-19-related sHLH (HScore: 180). He received three doses and his inflammatory parameters improved. He then deteriorated until he was on maximal inotropic and ventilator support. Given his extremely poor prognosis, he was commenced on RXB in a final attempt to treat sHLH (HScore: 230), as well as treatment dose LMWH. Within 48 hours, he was apyrexial and had improved biochemically. After two weeks of RXB, a weaning course of prednisolone (10 mg) was completed. He was successfully extubated on day 53 and stepped down from ITU on day 56. He was discharged nine weeks after his admission. Distinct differences between typical sHLH and that associated with COVID-19 have been noted; the latter is lung-centric, with an emergent acute respiratory distress syndrome (ARDS) and absence of organomegaly. (13) There is therefore a diagnostic challenge to distinguish between COVID-19 ARDS and patients with additional sHLH. The magnitude of the raised cytokine levels may not be reliable in differentiating from other causes of elevated cytokines and dependable cut-off values do not exist. (13) In order to recognise sHLH in COVID-19, monitoring inflammatory markers along with calculation of the 'HScore' may be useful. This is a clinical score which was developed to predict the likelihood of sHLH, encompassing one cytologic, three clinical and five biologic variables. (14) We utilise a modified version through exclusion of the non-mandatory bone marrow haemophagocytosis criteria; an adjusted score of >130 was considered to accurately classify the presence, or otherwise, of sHLH in 90% of patients. Both patients presented here, each receiving dual anti-cytokine treatments, were immunocompromised. They received treatment for sHLH and in both cases the use of a single agent did not lead to sustained clinical improvement. TCZ and RXB were given in differing sequences, but the addition of the second agent served to reverse a life-threatening situation. Both patients had a dramatic clinical improvement, normalisation of inflammatory markers and were ultimately discharged. This article is protected by copyright. All rights reserved Haematological experience of these agents, (15, 16) together with the data presented here, suggests IL-6 inhibition induces rapid cytokine suppression, whilst JAK-STAT inhibition administered over a longer period may help to sustain this response. These cases highlight that there is a need for recognition of sHLH in severe COVID-19 and indicate that there may be a role for the use of combination anti-cytokine treatment in the context of severe disease in high-risk patients. There are increasing numbers of anti-cytokine agents being used in clinical trials and our experience highlights the potential combination of RXB and TCZ in severe COVID-19 infection, which appears to have been well tolerated by both patients. In both our patients, a rapid reduction in the inflammatory markers needed a further sustained response and this was possible with the use of JAK-STAT inhibitor, alongside the TCZ. Pacritinib and Baricitinib are JAK inhibitors entering clinical trials to target the inflammatory state secondary to COVID-19, but may also have anti-viral properties (9) . The JAK-inhibitors may be late in coming to the COVID-19 party but are certainly beginning to look like one of the game changers in the fight against severe hyper inflammation. We do not have levels of IL-6 to account for in vivo activity of TCZ, but the monitoring of the inflammatory parameters certainly provides indirect evidence for the role of immunomodulators in the management of severe COVID infection. There is a need to understand the implications of significant immunosuppression, possibly leading to secondary infections; information on toxicity and efficacy can be obtained by well conducted larger studies, which is the need of the hour. Figure 1 (a COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet The pathogenesis and treatment of the 'Cytokine Storm'' in COVID-19 SARS-CoV-2 Infection Associated Hemophagocytic Lymphohistiocytosis: An autopsy series with clinical and laboratory correlation. medRxiv Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19 Immunotherapeutic implications of IL-6 blockade for cytokine storm Why tocilizumab could be an effective treatment for severe COVID-19? Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, singlecentre, pilot trial. The Lancet Haematology COVID-19: combining antiviral and anti-inflammatory treatments Emerging pharmacotherapies for COVID-19 Randomised Evaluation of COVID-19 Therapy -Full Text View -ClinicalTrials.gov The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease Development and validation of the hscore, a score for the diagnosis of reactive hemophagocytic syndrome Tocilizumab and the risk of respiratory adverse events in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised controlled trials. Clinical and experimental rheumatology Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis All the authors were equally involved in all stages of the manuscript preparation.Disclosures PN-Honararia from Novartis, others-none to declare. This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved